Zepbound (tirzepatide) is a dual agonist that targets two critical pathways in the body: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
While it isn't a quick-fix painkiller, consistent use can help your body recover more quickly from the inflammatory peak of your cycle
Someone with a highly responsive GLP1R variant may achieve significant weight loss at lower doses, while another person with a different genetic profile might require higher doses or see more modest initial results
Phentermine and tirzepatide represent two distinct pharmacological approaches to weight management, each with unique mechanisms of action and clinical applications
Step 1: Insurance Verification Start by completing a brief form detailing your health history and insurance information
GLP-1 receptor agonists are licensed in the UK for type 2 diabetes and weight management, including semaglutide, dulaglutide, and liraglutide These medications reduce HbA1c by approximately 1.01.5 percentage points and improve both fasting and post-meal glucose levels Weight loss associated with GLP-1 therapy can lead to secondary improvements in insulin resistance, particularly through reduction of visceral fat Common side effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhoea, which typically diminish over several weeks NICE recommends continuation only if patients achieve at least 1.0 percentage point HbA1c reduction within six months of treatment initiation Patients with diabetic retinopathy require close monitoring, and GLP-1 medications should be discontinued at least two months before planned pregnancy Table of Contents What Are GLP-1 Receptor Agonists and How Do They Work
